Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Non-Canonical Activin A Signaling Stimulates Context-Dependent and Cellular-Specific Outcomes in CRC to Promote Tumor Cell Migration and Immune Tolerance.
Wiley MB, Bauer J, Mehrotra K, Zessner-Spitzenberg J, Kolics Z, Cheng W, Castellanos K, Nash MG, Gui X, Kone L, Maker AV, Qiao G, Reddi D, Church DN, Kerr RS, Kerr DJ, Grippo PJ, Jung B. Wiley MB, et al. Among authors: nash mg. Cancers (Basel). 2023 May 31;15(11):3003. doi: 10.3390/cancers15113003. Cancers (Basel). 2023. PMID: 37296966 Free PMC article.
Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
Gore JL, Wolff EM, Comstock BA, Follmer KM, Nash MG, Basu A, Chisolm S, MacLean DB, Lee JR, Lotan Y, Porten SP, Steinberg GD, Chang SS, Gilbert SM, Kessler LG, Smith AB; CISTO Collaborative. Gore JL, et al. Among authors: nash mg. BMC Cancer. 2023 Nov 18;23(1):1127. doi: 10.1186/s12885-023-11605-8. BMC Cancer. 2023. PMID: 37980511 Free PMC article.
The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient-centered trial.
Nathan KK, Follmer KM, Nash MG, Wolff EM, Lee JR, Mecham S, Yano M, Kim SM, Comstock BA, Gore JL, Smith AB. Nathan KK, et al. Among authors: nash mg. Cancer. 2025 Jan 1;131(1):e35600. doi: 10.1002/cncr.35600. Epub 2024 Oct 14. Cancer. 2025. PMID: 39400910
Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients.
Boothby AB, Tanner MK, Alswied A, Youngs D, Bribiesca Rodriguez J, Bikkani T, Cha N, Gernsheimer T, Gimferrer I, Hess JR, Sokol-Hessner L, Marivada S, Nash MG, Flegel WA, Vassallo RR, Stroncek DF, Tsang HC, Panch SR. Boothby AB, et al. Among authors: nash mg. Blood Adv. 2024 Sep 10;8(17):4689-4699. doi: 10.1182/bloodadvances.2024014143. Blood Adv. 2024. PMID: 39028936 Free PMC article.
Protocol to measure validity and reliability of colorectal, breast, cervical and lung cancer screening questions from the 2021 National Health Interview Survey: Methodology and design.
Kessler LG, Comstock B, Aiello Bowles EJ, Mou J, Nash MG, Bravo P, Fleckenstein LE, Pflugeisen C, Gao H, Winer RL, Ornelas IJ, Smith C, Neslund-Dudas C, Shetty P. Kessler LG, et al. Among authors: nash mg. PLoS One. 2024 Mar 4;19(3):e0297773. doi: 10.1371/journal.pone.0297773. eCollection 2024. PLoS One. 2024. PMID: 38437207 Free PMC article.
23 results